Unicycive therapeutics.

Item 1.01. Entry into a Material Definitive Agreement. On March 3, 2023, Unicycive Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (the "Investors"), pursuant to which the Company agreed to issue and sell, in a private placement (the "Offering"), 30,190 shares of Series A-1 Convertible Preferred Stock ...About Unicycive Therapeutics, Inc. Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using ...Dec 29, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS ...Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...

LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has entered a licensing agreement with Spectrum Pharmaceuticals for Renazorb (lanthanum dioxycarbonate), a late-stage asset for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...

LOS ALTOS, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.Sep 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. As of March 9, 2023, the average one-year price target for Unicycive Therapeutics is $9.56. The forecasts range from a low of $3.03 to a high of $14.18. The average price target represents an ...Unicycive Therapeutics Inc UNCY shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb, a ...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA. UNCY - Unicycive Therapeutics Inc - Stock screener for investors and traders, financial …

Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022) Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net ...

0. As of December 4, 2023, Unicycive Therapeutics (NASDAQ: UNCY) has received positive analyst coverage and recommendations. Bruce Jackson from Benchmark has reaffirmed his Speculative Buy rating for Unicycive Therapeutics, setting a $3 price target. Additionally, EF Hutton has also reiterated its coverage of the company with a Buy …Unicycive Therapeutics Inc UNCY is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and their ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov 29, 2021 · Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being ...

Unicycive draws Buy rating at Roth on prospects for lead asset Apr. 06, 2023 10:53 AM ET Unicycive Therapeutics, Inc. (UNCY) By: Dulan Lokuwithana , SA News Editor 1 Comment tarabirdGet the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...We would like to show you a description here but the site won’t allow us.

UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com. Investor Contact: [email protected] (650) 900-5470. Anne Marie Stern Investor Relations [email protected] 212-362-1200. SOURCE: Unicycive Therapeutics, Inc ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent ...Thanksgiving is a time of gratitude, family, and gathering around a bountiful meal. While it’s often seen as a holiday for children, adults can also find joy and relaxation during this festive season. One activity that has gained popularity...Nov 30, 2023 · Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Unicycive Therapeutics has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Previous Next SCAI-003 Sunitinib. Wet age-related macular degeneration (wet AMD) is a disastrous disease of vision impairment in the macular region of the retina due to abnormalAarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...6 Sept 2023 ... Sara Kenkare-Mitra, PhD is currently President and Head of Research and Development at Alector where she leads all aspects of the company's R&D ...Jul 20, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Nov 29, 2021 · Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being ...

Unicycive Therapeutics Stock Performance. Shares of Unicycive Therapeutics stock opened at $0.52 on Monday. Unicycive Therapeutics has a 52-week low of $0.40 and a 52-week high of $2.87. The stock has a market capitalization of $18.07 million, a price-to-earnings ratio of -0.30 and a beta of 2.64.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18 ...

Contact - Unicycive. 4300 El Camino Real, Suite #210. Los Altos, CA 94022. +1 (650) 351-4495. Name. First Last. Contact Unicycive Therapeutics (UNCY) to learn more about our developing treatments for medical conditions. About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...Mar 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ... About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...Feb 2, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s.Unicycive Therapeutics Rebounds and Closes Up 17%. By Luisa Beltran. Updated July 13, 2021, 6:24 pm EDT / Original July 13, 2021, 10:36 am EDT. Share. Resize. Reprints.Nov 14, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...

Aug 16, 2021 · Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of. As of. December 31, June 30, 2020. 2021 (unaudited) Assets. Current assets: Cash $-$ 1. Prepaid related party service fee-38. Deferred offering costs. 200. 864. Prepaid expenses and other current assets. 4. 10. Total current assets. 204 ... Unicycive Therapeutics Inc UNCY is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and their ...Dec 28, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Instagram:https://instagram. glencore plc stockmerrill edge futures tradinghumans of ny court caselowe depot UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com. Investor Contact: [email protected] (650) 900-5470. Anne Marie Stern Investor Relations [email protected] 212-362-1200. SOURCE: Unicycive Therapeutics, Inc ... mondelzfinancial planners in pittsburgh Dec 1, 2023 · When is Unicycive Therapeutics's earnings date? Unicycive Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off last year's report dates. Learn more on UNCY's earnings history. xau index View the latest Unicycive Therapeutics Inc. (UNCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.Discover historical prices for UNCY stock on Yahoo Finance. View daily, weekly or monthly format back to when Unicycive Therapeutics, Inc. stock was issued.Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s